Atossa Therapeutics (ATOS)
Develops oral (Z)-endoxifen for breast cancer and selected rare diseases.
Something off on this page? Send us feedback.
Develops oral (Z)-endoxifen for breast-cancer settings and selected rare-disease evaluation. A clinical-stage biopharmaceutical company, it has no approved candidate and remains dependent on clinical, regulatory, manufacturing, partner, intellectual-property, and financing activities.
Development centers on the company's oral (Z)-endoxifen program, a selective estrogen receptor modulator and degrader in Phase 2 clinical development for breast-cancer treatment and risk-reduction settings. The program is also being evaluated for selected rare diseases.
Operations are based in Seattle and have focused on therapeutics since the business moved away from its original breast-health diagnostics and device model. No product candidate is approved for any indication.
Progress and continued program development depend on clinical development, regulatory interactions, manufacturing and third-party relationships, intellectual property, and financing while the company operates at a loss.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Jul 7, 2026 | Rodman & Renshaw | Initiate | Buy | |
| Feb 12, 2026 | Craig-Hallum | Target | $10 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $26.1M · Total debt $0 · Total assets $32.3M · Shareholders' equity $26.8M
- Revenue
- $0
- Operating income
- −$8.7M
- Net income
- −$8.5M
No dividends on record.
| Institutions34 holders · as of Mar 31, 2026 | 12.43% | 1.24M shares | |
| Insiders8 holders · as of May 14, 2026 | 2.14% | 213.4K shares | |
| Otherremainder | 85.43% | 8.53M shares |
9.98M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 3.50% | 349,096 | 13Fas of Mar 31, 2026 |
Ameriprise Financial IncInstitution | 2.56% | 255,134 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 1.33% | 133,169 | 13Fas of Mar 31, 2026 |
Renaissance Technologies LLCInstitution | 1.09% | 109,007 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.97% | 97,061 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
No open-market trades in the last 12 months.
- Olema Pharmaceuticals
Phase 3 oral ER antagonist/degrader for ER+/HER2− breast cancer
- Eli Lilly
Approved oral ER antagonist for ESR1-mutated breast cancer
- Arvinas
Approved oral ER degrader for ESR1-mutated breast cancer
- AstraZeneca (ADR)
Phase 3 oral SERD for HR+/HER2− advanced breast cancer
- Novartis (ADR)
Breast-oncology endocrine-therapy backbone with Kisqali
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Atossa Therapeutics | $2.49 | +2.89% | $24.5M | — | — | — | — |
| Olema Pharmaceuticals | $10.99 | +1.38% | $946.0M | — | — | — | — |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Arvinas | $9.61 | +0.21% | $618.8M | 59.9 | — | 2.0 | +1,014.7% |
| AstraZeneca (ADR) | $163.26 | +0.99% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 31.7 | 17.3 | 4.9 | +27.0% |